Joyce M. Slingerland, M.D., Ph.D.
Dr. Slingerland has a longstanding track record in funded breast cancer research. Her work has focused on cell cycle regulation and signal transduction via the TGF- β, MEK, Src and PI3K pathways. She discovered the cell cycle inhibitor p27, and her work has contributed to understanding the G1 to S phase transition and how aberrant signal transduction in cancer cells disrupts cell cycle regulators. She has investigated the use of targeted therapies with MEK and Src inhibitors to reverse antiestrogen resistance in breast and ovarian cancer. Her research studies the effects of oncogenic PI3K signaling on cell cycle, EMT, invasion and metastasis, and stem cell function. Recent work has focused on understanding heterogeneity, and hierarchies in breast cancer stem cells may contribute to resistance to anti-cancer therapies. Current funded research also investigates how VEGF, cytokines, and contact with adipose tissue affects mammary stem cell self-renewal.